. Author manuscript; available in PMC: 2018 Nov 15.

Published in final edited form as: Cancer Res. 2017 Nov 15;77(22):6462–6469. doi: 10.1158/0008-5472.CAN-17-1903

Table 5.

Type 2 diabetes in relation to ER+ and ER− breast cancer incidence, within strata of body mass index (BMI) and waist-hip ratio (WHR)

	ER+ breast cancer		ER− breast cancer

	Cases	MV HR (95% CI)	Cases	MV HR (95% CI)
BMI < 30kg/m²
No diabetes	494	Reference	264	Reference
Type 2 diabetes	21	0.86 (0.55–1.33)	22	1.92 (1.22–3.04)
BMI ≥ 30 kg/m²
No diabetes	342	Reference	161	Reference
Type 2 diabetes	51	1.07 (0.79–1.46)	19	1.05 (0.64–1.72)
WHR < 85
No diabetes	532	Reference	274	Reference
Type 2 diabetes	38	1.13 (0.81–1.60)	22	1.55 (0.99–2.45)
WHR ≥ 85
No diabetes	210	Reference	114	Reference
Type 2 diabetes	25	0.81 (0.53–1.24)	16	1.26 (0.72–2.18)

HRs adjusted for age, BMI at age 18, parity, age at first birth, age at menarche, duration of oral contraceptive use, duration of menopausal hormone use, and first degree family history of breast cancer.

p-value for interaction of type 2 diabetes with BMI: 0.20 for ER+ and 0.05 for ER−

p-value for interaction of type 2 diabetes with WHR: 0.22 for ER+ and 0.40 for ER−